Core Insights - Ultragenyx Pharmaceutical (RARE) has received FDA acceptance for its investigational new drug (IND) application for UX016, aimed at treating GNE myopathy (GNEM) [1][7] Company Overview - Ultragenyx Pharmaceutical has developed a portfolio of four therapies: Crysvita, Mepsevii, Dojolvi, and Evkeeza, targeting various rare diseases [8] Disease Background - GNE myopathy (GNEM) is a rare inherited neuromuscular disorder caused by reduced production of sialic acid, leading to severe muscle wasting and disability [2] Clinical Development Plan - The clinical development of UX016 is externally funded by a patient organization, with a phase I/II study expected to start in the second half of 2026, enrolling approximately 24 adults [4][5] Study Design & Objectives - The study will assess the safety, effectiveness, and pharmacokinetics of UX016, comparing two dose levels against a placebo over an initial 12-week period, followed by evaluations of muscle strength and functional improvements through 48 weeks [5][6] Drug Mechanism - UX016 is designed as a prodrug that combines sialic acid with a hydrophobic fatty acid tail to enhance its delivery to muscle, addressing limitations of previous therapies [6][7] Market Performance - Year to date, RARE's shares have decreased by 16.1%, contrasting with the industry's growth of 0.3% [2]

Commercial Success - The company has experienced significant commercial success driven by Crysvita, showing double-digit growth year-over-year [1] - Other products such as Dojolvi and Evkeeza are also contributing to this growth, with Mepsevii providing additional support [1] Pipeline Development - A major focus is on the Angelman syndrome program, with data readout expected in the second half of the year [2] - Progress is being made in the gene therapy pipeline, with a PDUFA date for GSDIa and Sanfilippo nearing completion [2] - The company is also advancing other projects related to OTC and Wilson disease, indicating a robust clinical pipeline [2]

Summary of Ultragenyx Pharmaceutical Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Date**: March 11, 2026 - **Key Speaker**: Eric Crombez, CMO Recent Events and Priorities - **Commercial Success**: - Crysvita continues to show double-digit year-over-year growth - Significant growth in Dojolvi and Evkeeza, with Mepsevii contributing to revenue [4][4] - **Pipeline Focus**: - Emphasis on Angelman syndrome with data readout expected in the second half of the year - Progress in gene therapy pipeline, particularly for GSDIa and Sanfilippo [4][4] Angelman Syndrome Study - **Phase 3 Study Design**: - Primary endpoint will be measured without caregiver input to control for placebo effects [6][7] - Previous Phase 1/2 showed a Bayley Cognition Score improvement of over 10, with a clinically significant difference set at 5 [9][13] - **Statistical Considerations**: - Study powered to show a 10.9 difference in cognition scores from baseline in treated patients, with a flat natural history curve for the placebo group [11][12] - **MDRI Endpoint**: - FDA has agreed to consider the Multi-Domain Responder Index (MDRI) as a secondary endpoint, which captures broader developmental aspects [16][18] Gene Therapy Dosing and Efficacy - **Dosing Strategy**: - Initial dosing informed by animal models, with adjustments made based on clinical data from Phase 1/2 [20][21] - **GTX-102 Potency**: - Claimed to be the most potent ASO in development for Angelman, based on clinical data from 74 patients [22][22] - **Knockdown and Protein Restoration**: - Achieving over 80% knockdown is necessary for clinical benefit, with expectations of around 35% expression needed for efficacy [25][27] DTX401 Gene Therapy - **BLA Acceptance**: - BLA for DTX401 accepted, with a PDUFA date set for August [30][30] - **Manufacturing Control**: - In-house manufacturing facility established to ensure quality and control over production [32][33] - **Durability of Treatment**: - Strong durability observed in Phase I/II patients, supporting confidence in FDA review [34][35] Commercial Opportunity - **Market Potential**: - Approximately 6,000 patients in the U.S. with GSDIa, with high penetration expected due to the necessity of treatment [42][42] Wilson Disease Program - **Efficacy Differentiation**: - Aiming to show positive differentiation from existing chelator treatments, with a focus on the majority of patients coming off chelators [48][49] - **Biomarker Confidence**: - Heparan sulfate is considered a strong biomarker for clinical benefit, with a shift towards clinical approval based on patient outcomes [46][47] Conclusion - Ultragenyx is focused on advancing its gene therapy pipeline, particularly for rare diseases like Angelman syndrome and GSDIa, with promising commercial opportunities and a strong emphasis on clinical efficacy and safety in its studies.

Summary of Ultragenyx Pharmaceutical FY Conference Call Company Overview - **Company Name**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Founded**: 2010, went public in 2014 - **Focus**: Rare diseases with high unmet medical needs, utilizing diverse platforms such as enzyme replacement therapy and gene therapy [2][3] Commercial Strategy - **Global Footprint**: Ultragenyx has established a broad commercial presence, including North America, Europe, Japan, and South America, allowing for direct control over product distribution and leveraging medical affairs expertise [3][4] - **Key Products**: The company’s commercialized products include Crysvita, Dojolvi, Mepsevii, and Evkeeza, with Crysvita being the leading product [3][5] Financial Outlook - **Profitability Goal**: The company aims to achieve profitability by 2027, driven by its base business and growth from existing products, alongside the approval and commercialization of late-stage programs [5][6] - **Pipeline Advancement**: The transition from late-stage trials to commercialization is expected to reduce costs significantly, with smaller investments in earlier phase trials [6] Pipeline Overview - **Lead Programs**: The near-term approval is anticipated for GSD1A, with a PDUFA date in August, followed by the Sanfilippo program. The Angelman program is also a significant focus, with phase 3 data readout expected later this year [8][10] - **Angelman Program**: The phase 3 studies, Aspire and Aurora, are crucial for understanding the drug's efficacy in patients with full deletions of the UBE3A gene [10][11] Clinical Trial Insights - **Cognition as Primary Endpoint**: The Bayley-IV cognitive score is chosen as the primary endpoint for the Angelman program, with a focus on foundational skills that impact overall development [13][15] - **Statistical Significance**: A 10.9-point improvement from baseline in cognition was observed in phase 1/2 trials, compared to a natural history change of 1.2, supporting the statistical power of the phase 3 study [15][16] Safety and Efficacy - **Safety Profile**: Concerns regarding lower extremity weakness were noted, with a mitigation plan in place to address potential injection site irritation [33][35] - **Comparative Analysis**: The company acknowledges competition from Ionis Pharmaceuticals in the Angelman space, with both companies awaiting phase 3 data for efficacy and safety comparisons [31][32] Unmet Medical Needs - **Patient Population**: The Angelman syndrome population is estimated at 60,000, with no current treatments available, highlighting a significant unmet need [48] - **Other Conditions**: Similar high unmet needs exist for Sanfilippo and GSD1A, where patients face severe developmental challenges without available therapies [48] Regulatory Considerations - **FDA Engagement**: The company has learned from previous experiences with the FDA, particularly regarding manufacturing issues, and remains confident in the strength of its data for upcoming submissions [49][50] Conclusion - **Future Updates**: The company is focused on the upcoming data readouts and maintaining high-quality standards in its clinical trials, with no immediate plans for additional updates until the phase 3 results are available [30][39]

Core Thesis - Ultragenyx Pharmaceutical Inc. is viewed positively due to its diversified rare disease portfolio and upcoming gene therapy catalysts, despite recent setbacks in clinical trials [1][5]. Financial Performance - The company generates approximately $670 million in annual revenue from four approved products [2]. - Ultragenyx experienced a cash burn of roughly $446 million in the first nine months of 2025, indicating an annualized burn rate of about $600 million against $735 million in cash, providing roughly 1.2 years of runway [4]. Clinical Pipeline - The company has a credible pipeline with significant upcoming events in 2026, including two gene therapy PDUFA decisions for UX111 and DTX401, and Phase 3 data for GTX-102 [2][3]. - UX111 aims to deliver SGSH across the blood-brain barrier, while DTX401 focuses on restoring G6Pase activity in the liver, showing promising Phase 3 data [3]. - GTX-102 targets the UBE3A gene in Angelman syndrome, although it faces challenges related to a narrow therapeutic window [3]. Risks and Challenges - The recent Phase 3 failure of setrusumab highlights the risk that biomarker success does not guarantee clinical benefit [2]. - Manufacturing issues previously led to a Complete Response Letter (CRL) for UX111, indicating potential operational risks [4]. - The intellectual property landscape is mixed, with some gene therapies benefiting from technical barriers, while others face challenges from licensing and generics [4].

Core Insights - The upcoming year is a pivotal moment for the company, with two potential product launches and a crucial data readout expected to significantly boost commercial revenue [1] - A strategic restructuring plan is being implemented to lower operating expenses and align resources with high-impact opportunities in the rare disease sector [2] FDA Update - The company received an Incomplete Response Letter (IRL) from the FDA regarding its resubmitted marketing application for UX111 (rebisufligene etisparvovec) gene therapy for Sanfilippo syndrome type A, requesting additional documentation for resubmission [3] Earnings Snapshot - The company reported a fourth-quarter loss of $1.29 per share, missing the consensus estimate of $1.14, while sales increased to $207 million from $165 million year-over-year, surpassing the consensus of $196.97 million [4] - Revenue from Crysvita was $145 million, Dojolvi reached $32 million, and Evkeeza sales were $17 million [4] Strategic Restructuring - A strategic restructuring plan has been initiated, including a 10% workforce reduction affecting approximately 130 employees, aimed at reducing expenses and partially reinvesting to support future growth [5] - The company aims to achieve profitability by 2027 through significant cost discipline and revenue growth from current and new product launches [5] Outlook - The company forecasts fiscal 2026 sales between $730 million and $760 million, below the consensus of $786.93 million, with Crysvita revenue expected to be between $500 million and $520 million and Dojolvi revenue projected at $100 million to $110 million [6] Market Reaction - Following the announcements, Ultragenyx Pharmaceutical shares fell by 10.21% to $21.10 [7]

Core Insights - Ultragenyx reported $207 million in revenue for Q4 2025, marking a year-over-year increase of 25.6% [1] - The company's EPS for the same period was -$1.29, an improvement from -$1.39 a year ago, but below the consensus estimate of -$1.20 [1] - The revenue exceeded the Zacks Consensus Estimate of $202.92 million by 2.01%, while the EPS fell short by 7.32% [1] Revenue Breakdown - Dojolvi generated $32 million in revenue, surpassing the average estimate of $30.28 million, with a year-over-year increase of 2.9% [4] - Evkeeza achieved $17 million in revenue, exceeding the estimated $16.37 million, reflecting a significant year-over-year growth of 63.9% [4] - Mepsevii reported $13 million in revenue, above the average estimate of $10.81 million, also showing a year-over-year increase of 63% [4] - Total Crysvita revenue reached $145 million, exceeding the average estimate of $135.25 million [4] - Overall product sales were $102 million, which was below the estimated $114.76 million, but still represented a year-over-year increase of 41.9% [4] - Royalty revenue amounted to $105 million, surpassing the average estimate of $91.57 million, with a year-over-year change of 12.9% [4] Stock Performance - Over the past month, Ultragenyx shares have returned -0.8%, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - Total revenue for 2025 was reported at $673 million, representing a 20% growth over 2024 and exceeding the upper end of guidance [11] - Net loss for the year was $575 million, or $5.83 per share [12] - Cash, cash equivalents, and marketable securities as of December 31 were $738 million [12] - Guidance for 2026 total revenue is expected to be between $730 million and $760 million, reflecting an 8%-13% growth over 2025 [12][13] Business Line Data and Key Metrics Changes - Crysvita contributed $481 million in revenue, with a 17% growth over 2024 [11] - Dojolvi generated $96 million, representing a 9% growth over 2024 [11] - Evkeeza saw significant growth, contributing $59 million, which is an 84% increase over 2024 [11] - Mepsevii contributed $37 million, continuing to treat patients in an ultra-rare indication [11] Market Data and Key Metrics Changes - The commercial business delivered a significant 20% year-over-year growth in 2025, with treatments reaching over 35 countries [8] - In Latin America, Crysvita's business is anchored in Brazil and Argentina, with solid reimbursement growth in Mexico and Colombia [16][17] - Dojolvi has seen continuous growth in EMEA, with regulatory wins in Kuwait and the U.K. [18] Company Strategy and Development Direction - The company aims for profitability by 2027, implementing a strategic restructuring plan to reduce operating expenses and align resources with high-impact opportunities [9][10] - The plan includes a 10% workforce reduction, impacting approximately 130 employees [10] - The company is focused on launching three additional treatments over the next two years while continuing to grow its base business of four commercial products [10][24] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2026 as a significant year with potential approvals in MPS IIIA and glycogen storage disease type Ia, along with pivotal data readout in Angelman syndrome [4] - The management expressed confidence in the ability to deliver the next phase of growth required to reach profitability [20] - The company is addressing the FDA's incomplete response letter regarding UX111 and is working on resubmitting the BLA with additional documentation [7][21] Other Important Information - The company has a strong commercial infrastructure and experienced team to execute complex rare disease therapies globally [20] - The strategic restructuring is expected to enable the company to diversify its pipeline beyond gene therapy [54] Q&A Session Summary Question: What was the decision behind using cognition as the primary endpoint for the Angelman study? - The decision was based on the belief that cognition is fundamental and intertwined with communication, which takes more time to develop [27] Question: Can you provide insights on the patient baseline profile for the Angelman study? - The baseline data from the phase II trial is reflective of the phase III program, and the company is comfortable with the comparability [33] Question: How does the company plan to achieve profitability in 2027? - The pathway to profitability includes continued growth from current products and a reduction in combined R&D and SG&A expenses [40][42] Question: What is the timeline for the resubmission of the BLA in response to the IRL? - The resubmission is expected to take a couple of weeks for the FDA to determine if all required documents are included, with a PDUFA date set approximately six months after resubmission [72] Question: What is the expected launch trajectory for GSDIa? - The market for GSDIa is expected to develop steadily, with strong demand anticipated, but not as urgent as MPS IIIA [76]

Financial Data and Key Metrics Changes - For 2025, the company reported total revenue of $673 million, representing a 20% growth over 2024, exceeding the upper end of guidance [11] - The net loss for the year was $575 million, or $5.83 per share, with cash, cash equivalents, and marketable securities totaling $738 million as of December 31 [12] - Guidance for 2026 expects total revenue between $730 million and $760 million, reflecting an 8%-13% growth over 2025 [12][13] Business Line Data and Key Metrics Changes - Crysvita contributed $481 million in revenue, with a 17% growth over 2024, while Dojolvi generated $96 million, representing a 9% growth [11] - Evkeeza saw significant growth of 84% over 2024, contributing $59 million, and Mepsevii contributed $37 million [11] - The company anticipates Crysvita revenue in 2026 to be between $500 million and $520 million, with Dojolvi expected to generate between $100 million and $110 million [13] Market Data and Key Metrics Changes - The commercial business delivered a significant 20% year-over-year growth in 2025, with treatments now available in over 35 countries [8] - In Latin America, Crysvita's business is anchored in Brazil and Argentina, with solid reimbursement growth in Mexico and Colombia [17] - Dojolvi continues to grow steadily in the U.S. and EMEA, with recent regulatory wins in Kuwait and the U.K. [18] Company Strategy and Development Direction - The company is focused on achieving profitability by 2027 through a strategic restructuring plan that includes a 10% workforce reduction and realignment of resources towards high-impact opportunities [9][10] - The company aims to launch three additional treatments over the next two years while continuing to grow its existing commercial products [10][24] - The strategic restructuring will allow the company to maintain a diversified pipeline, not solely focused on gene therapy [54] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming year, highlighting key inflection points with potential approvals in MPS IIIA and glycogen storage disease type Ia, as well as pivotal data readouts in Angelman syndrome [4][20] - The management acknowledged the challenges posed by the FDA's incomplete response letter regarding UX111 but emphasized their commitment to providing the necessary documentation for resubmission [7][52] - The company remains optimistic about its ability to deliver meaningful growth and reach profitability, supported by a strong commercial infrastructure and ongoing product launches [20][42] Other Important Information - The company has implemented a strategic restructuring plan to reduce operating expenses and align resources with high-impact opportunities, aiming for profitability in 2027 [9][10] - The company expects R&D and SG&A expenses to decrease significantly in 2027, driven by the completion of clinical studies and reduced early-stage research efforts [15] Q&A Session Summary Question: Can you explain the choice of cognition as the primary endpoint for the Angelman study? - The decision was based on the fundamental nature of cognition and its interrelation with communication, with a focus on a broader assessment through the Multidomain Responder Index [27][28] Question: What is the baseline profile of patients in the Angelman study? - The baseline data from the phase 2 trial is reflective of the phase 3 program, and the company is comfortable with the comparability of the cohorts [33] Question: How does the company plan to achieve profitability in 2027? - The pathway to profitability includes continued growth from existing products, cost reductions, and contributions from upcoming launches [38][40] Question: What is the status of the DTX-301 program? - The DTX-301 program is ongoing, with data expected to be released this year [49] Question: Can you provide an update on the UX111 program and the IRL received? - The company is preparing to provide comprehensive documentation to address the IRL issues and is committed to resubmitting the BLA [52][53]

Financial Data and Key Metrics Changes - For 2025, the company reported total revenue of $673 million, representing a 20% growth over 2024, exceeding the upper end of guidance [10] - The net loss for the year was $575 million, or $5.83 per share, with cash, cash equivalents, and marketable securities totaling $738 million as of December 31 [11] Business Line Data and Key Metrics Changes - Crysvita contributed $481 million, with a 17% growth over 2024, exceeding guidance [10] - Dojolvi generated $96 million, reflecting a 9% growth over 2024 [10] - Evkeeza saw significant growth, contributing $59 million, representing an 84% increase over 2024 [10] - Mepsevii contributed $37 million, continuing to treat patients in an ultra-rare indication [10] Market Data and Key Metrics Changes - The commercial business delivered a significant 20% year-over-year growth in 2025, with treatments reaching over 35 countries [6] - The company anticipates total revenue in 2026 to be between $730 million and $760 million, representing an 8%-13% growth over 2025 [11][12] Company Strategy and Development Direction - The company is focused on achieving profitability by 2027 through a strategic restructuring plan that includes a 10% workforce reduction and realignment of resources towards high-impact opportunities [7][9] - The company aims to launch three additional treatments over the next two years while continuing to grow its existing commercial products [9][22] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2026 as a significant year with potential approvals in key programs and pivotal data readouts [3] - The company is addressing the FDA's incomplete response letter regarding UX111 and is working to provide additional documentation for resubmission [5][20] - Management expressed confidence in the ability to deliver the next phase of growth required to reach profitability [19] Other Important Information - The company is implementing a strategic restructuring plan to reduce operating expenses while advancing its product pipeline [7][9] - The company expects combined R&D and SG&A expenses to be flat to down low single digits in 2026 compared to 2025 [12] Q&A Session Summary Question: Regarding the primary endpoint for the phase 3 Angelman study - The decision to use cognition over expressive communication was based on its fundamental importance and the complexities of communication development [24][25] Question: Can you provide insights on the patient baseline profile for the phase 3 study? - The baseline data from the phase 3 program is comparable to the expansion trial, providing confidence in the study's design [29][30] Question: How does the company plan to achieve profitability in 2027? - The pathway to profitability includes continued growth from current products and cost reductions, with expectations for combined R&D and SG&A expenses to decrease significantly by 2027 [35][36] Question: Can you clarify the timeline for the IRL resubmission? - The resubmission timeline is similar to the original submission, with a PDUFA date expected approximately six months after resubmission [68][69] Question: What is the expected launch trajectory for DTX-401? - The launch is expected to develop steadily, with strong demand anticipated, but not an immediate steep uptake [72]